Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravenous ferric derisomaltose in non-anemic iron-deficient colorectal cancer patients before surgery
2019-003819-56Phase 2Active
- Sponsor
- Center for Surgical Science
- Start
- Jan 2020
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ferric derisomaltose in iron deficiency anemia (IDA) and colorectal cancer (CRC) (2 arms), sponsored by Center for Surgical Science. Primary endpoints: Change in cellular respiration, Preoperative change in neutrophil-to-lymphocyte ratio and 1 more. Started Jan 2020; status: active.
02
Drugs
ferric derisomaltose
03
Conditions
iron deficiency anemia (IDA)colorectal cancer (CRC)
Beyond the preview
Go deeper on 2019-003819-56.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003819-56.